FDA approves Roche’s Xofluza for Influenza post-exposure prophylaxis
Roche has announced that the U.S. FDA has granted supplemental New Drug Application (sNDA) approval for Xofluza, the first single-dose
Read more
Oncology
EC approves GSK’s Zejula for advanced ovarian cancer treatment
Zejula (niraparib), developed by pharma giant GSK, has become the first polymerase (PARP) inhibitor approved as monotherapy in the EU for
Read more
Phenomic AI starts with $6M using AI/ML for Targeting the Tumor Stroma
Phenomic AI, a Canadian biotechnology company that uses an AI/ML platform for targeting the tumor stroma, has launched with $6
Read more
FDA approves Roche’s Venclexta combos for acute myeloid leukaemia
Roche revealed on Monday that Venclexta ® (venetoclax) in conjunction with azacitidine or decitabine or low-dose cytarabine (LDAC) has been
Read more
J&J Covid-19 Vaccine produces a strong neutralizing antibody response
Interim analysis of the J&J COVID-19 vaccine candidate (JNJ-78436735) in the ongoing Phase 1/2a clinical trial has shown that a
Read more
HPAPI and ADC manufacturing facility, Merck KGaA, Wisconsin, USA
Darmstadt headquartered Merck KGaA, a leading science and technology company operating in the U.S. & Canada as MilliporeSigma, has announced a
Read more
Merck to licence two preclinical immuno oncology programs from F-star
Two additional preclinical discovery programs will be added to the Merck KGaA and F-star Therapeutics collaboration. Merck KGaA, Darmstadt, Germany
Read more
FDA clears Deciphera Pharmaceuticals’ QINLOCK™ (ripretinib) for GIST
Deciphera Pharmaceuticals, Inc. has revealed that QINLOCK™ (ripretinib) was formally authorised by the U.S. Food and Drug Administration (FDA) for
Read more
FDA approves Lynparza as maintenance treatment with bevacizumab for HRD-positive ovarian cancer
AstraZeneca and Merck & Co have received the FDA’s approval for Lynparza (olaparib) as 1st-line maintenance treatment with bevacizumab for
Read more
Inovio Pharmaceuticals Stock up 16.36% as HPV drug shows promise
Inovio Pharmaceuticals stock soared by +16.36% on Friday, as HPV drug VGX-3100 showed promise in Phase 2 Trial. Shares of
Read more